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 21 
ABSTRACT 22 
 23 
Purpose 24 
The automated high-throughput Abbott RealTime MTB real-time PCR assay has been recently launched 25 
for Mycobacterium tuberculosis complex (MTBC) clinical diagnosis. This study would like to evaluate 26 
its performance.  27 
Methods 28 
We first compared its diagnostic performance with the Roche Cobas TaqMan MTB assay on 214 clinical 29 
respiratory specimens. Prospective analysis of a total 520 specimens was then performed to further 30 
evaluate the Abbott assay. 31 
Results 32 
The Abbott assay showed a lower limit of detection at 22.5 AFB/ml, which was more sensitive than the 33 
Cobas assay (167.5 AFB/ml). The two assays demonstrated significant difference in diagnostic 34 
performance (McNemar’s test; P=0.0034), which the Abbott assay presented significantly higher area 35 
under curve (AUC) than the Cobas assay (1.000 vs 0.880; P=0.0002). The Abbott assay demonstrated 36 
extremely low PCR inhibition on clinical respiratory specimens. The automated Abbott assay required 37 
only very short manually handling time (0.5 hour), which could help to improve the laboratory 38 
management. In the prospective analysis, the overall estimates for sensitivity and specificity of the 39 
Abbott assay were both 100% among smear-positive specimens, whereas the smear-negative specimens 40 
were 96.7% and 96.1% respectively No cross-reactivity with non-tuberculosis mycobacterial species was 41 
observed. The superiority in sensitivity of the Abbott assay for detecting MTBC in smear-negative 42 
specimens could further minimize the risk in MTBC false negative detection.  43 
Conclusion 44 
The new Abbott RealTime MTB assay has good diagnostic performance which can be a useful diagnostic 45 
tool for rapid MTBC detection in clinical laboratories. 46 
 47 
(Word count: 238 words) 48 
Keywords: Mycobacterium tuberculosis, real-time PCR, clinical diagnosis 49 
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 51 
INTRODUCTION 52 
 53 
Tuberculosis can cause high mortality and it has been a global public health problem for decades 54 
[1]. In highly endemic region like Hong Kong, acid-fast bacilli (AFB) smear microscopy and 55 
mycobacterial culture on selective solid media (Lowenstein-Jensen and Stonebrink medium) was used 56 
as conventional methods for Mycobacterium tuberculosis complex (MTBC) detection [2-5]. However, 57 
due to the low sensitivity of AFB smear and the long turn-around-time of mycobacterial culture, PCR-58 
based detection assays have been introduced for rapid detection of MTBC DNA from clinical specimens 59 
[6]. Commercial assays such as the Cobas Amplicor MTB or the Cobas TaqMan MTB assay (Roche 60 
Diagnostics, Switzerland) has been widely used in clinical mycobacteriology laboratories for direct 61 
specimen detection of MTBC DNA in the recent 20 years [7, 8]. These assays could significantly reduce 62 
the diagnostic time from weeks to hours, which can greatly improve patient care and infection control. 63 
 Recently, Abbott Molecular (Des Plaines, IL) has introduced an automated RealTime MTB 64 
PCR assay for in vitro diagnostic purpose. This in-vitro diagnostic (CE-IVD) marked assay includes an 65 
automated extraction step, which can manage a maximum of 96 specimens in a single batch, and a real-66 
time PCR-based amplification that specifically targets two MTBC genes, the insertion sequence 6110 67 
(IS6110) and protein antigen b (PAB) in a single reaction [9, 10]. The presence of multiple copies of 68 
IS6110 gene in some MTBC can certainly increase the diagnostic sensitivity of the assay. 69 
In this study, we compared the diagnostic performance of the new Abbott assay with the Roche 70 
Cobas TaqMan MTB assay (Roche Diagnostics, Switzerland). A prospective analysis of the Abbott 71 
system was also performed on 535 clinical respiratory specimens requesting for mycobacterium culture. 72 
The performance of the Abbott system was further compared with the conventional AFB smear staining 73 
and culture results.  74 
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METHODS AND MATERIALS 75 
 76 
Specimen collection and sample processing 77 
A total of 535 sputum specimens were available from adult patients with chest symptoms and/or 78 
chest radiographic infiltrates of undetermined origin between 4 December 2013 and 24 March 2014 in 79 
Queen Mary Hospital and Chest Clinics. Clinical and treatment history of these patients were collected 80 
for culture-PCR discrepancy analysis. All clinical specimens were first examined by fluorescence 81 
Auramine O and Ziehl-Neelsen staining for AFB. The sputum specimens were then decontaminated and 82 
concentrated as described previously [2]. The digested sediments were divided equally for mycobacterial 83 
culture and subsequent PCR assays. Mycobacterial cultures were grown on Lowenstein-Jensen and 84 
Stonebrink medium with incubation for 6 weeks. Positive AFB cultures were identified as described 85 
previously [7, 11]. The species identification of non-tuberculosis mycobacteria (NTM) was determined 86 
by 16S rRNA gene sequencing [12]. 87 
For the first 214 specimens collected during the study, parallel run on the Roche Cobas TaqMan 88 
MTB assay and the Abbott RealTime MTB assay would be performed. For the other 221 specimens 89 
collected afterwards, only the Abbott assay would be performed. For specimens demonstrated to be PCR 90 
positive, they were further confirmed by using the Cobas TaqMan MTB assay. On the other hand, the 91 
limit of detection (LOD) for both assays was further evaluated by 8 serial dilutions of the M. tuberculosis 92 
H37Rv control strain (0-100,000 AFB per ml) spiking into AFB negative sputum. The number of AFB 93 
in each dilution was confirmed by actual count on bacterial culture colonies grown on Middlebrook 7H10 94 
agar after 6 weeks incubation. This study protocol has been approved by the institutional review board 95 
(IRB Reference Number: UW 12-309). 96 
 97 
Cobas TaqMan MTB assay 98 
The Cobas TaqMan MTB assay which included 2 major steps, the DNA extraction and PCR 99 
amplification was conducted according to the manufacturer’s instructions [13]. Briefly, 0.5 ml of each 100 
digested sediment was mixed with same volume of wash solution and centrifuged. The supernatant was 101 
discarded and the pellet was lysed. Finally, the mixture was incubated and neutralized. MTB DNA was 102 
then extracted by using the Cobas Amplicor Respiratory Specimen Preparation Kit (Roche Diagnostics, 103 
Switzerland). Fifty microliters of DNA extract were used for each PCR reaction by using the Cobas 104 
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 5 
TaqMan 48 Analyzer (Roche Diagnostics, Switzerland) with positive and negative controls. A maximum 105 
of 48 samples could be performed per run. One negative control and 1 positive control were included in 106 
each run, therefore allowing a maximum of 46 specimens to be processed per run. 107 
 108 
Abbott RealTime MTB automated assay 109 
The RealTime MTB automated assay included a simple manual sample inactivation step and 110 
the automated sample preparation and amplification steps. A maximum of 96 samples could be 111 
performed per run. One negative control and 1 positive control were included in each run, therefore 112 
allowing a maximum of 94 specimens to be processed per run. For sample inactivation, 0.5ml of each 113 
digested sediment was manually mixed with 1.5ml inactivation reagent (0.4M NaOH, 60% Isopropanol 114 
and 0.18% Tween-20). The mixtures were incubated for at least 1 hour but no more than 24 hours before 115 
loading into the Abbott m2000sp instrument for nucleic acid extraction. Sample preparation step was 116 
then performed automatically in the Abbott m2000sp instrument by using the mSample Preparation 117 
System DNA kit. Twenty-five microliters of extraction elutate were then mixed with 25 μl amplification 118 
reagent mix from the RealTime MTB Amplification Reagent Kit. The sample amplification step was 119 
then performed in the Abbott m2000rt real-time PCR thermocycler with the “RealTime MTB assay 120 
application” protocol. 121 
 122 
Statistical analysis 123 
The diagnostic performance of PCR was evaluated against that of bacterial culture plus medical 124 
history including chest X-ray and clinical coughing symptoms as gold standard. The sensitivities, 125 
specificities, positive predictive values (PPVs), and negative predictive values (NPVs) were calculated 126 
based on the results of concurrently performed mycobacterial cultures. The area under curve (AUC) 127 
calculated from the receiver operating characteristic (ROC) curve that generated by the MedCalc 128 
software version 14.12.0 (MedCalc Software, USA) were compared between the two methods for 129 
performance evaluation. The correlation of the two assays was also compared by the McNemar’s test. 130 
  131 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
 6 
RESULTS 132 
 133 
Limit of detection for the Abbott RealTime MTB assay 134 
Serial dilutions of the MTB standard strain H37Rv were used to compare the LOD of the Abbott 135 
and Cobas assays. The average LOD for each assay was determined by the average of 2 serial dilution 136 
sets of H37Rv (Table 1). The Cobas TaqMan MTB assay was found to have an average LOD at 167.5 137 
AFB/ml (Cp value = 44.7) while the Abbott assay demonstrated to have an average LOD at 22.5 AFB/ml 138 
(Ct value = 39.0). 139 
 140 
Comparative analysis of the Abbott RealTime MTB and Roche Cobas TaqMan MTB assays 141 
The first 214 clinical sputum specimens received from the chest clinic were subjected in parallel 142 
to the Cobas TaqMan MTB and Abbott assays. No PCR inhibition was observed in the Abbott RealTime 143 
MTB assay, while there were 23 specimens demonstrated PCR inhibition in the Cobas TaqMan MTB 144 
assay and they were removed from the comparative analysis. The other 191 non-inhibited specimens 145 
were eligible for the analysis of diagnostic performance of the two assays (Table 2).  146 
The overall diagnostic sensitivity was 100% for the Abbott assay and 76.1% for the Cobas 147 
assay, while the overall diagnostic specificity for the Abbott and Cobas assay was both 99.3% (Table 2). 148 
The McNemar’s test results (P=0.0034) showed that the two assays had significant difference in 149 
diagnostic performance for clinical respiratory specimens. The ROC curve for the two assays showed 150 
that the AUC was 1.000 for the Abbott assay with optimal Ct cut-off value at 40.7 and 0.880 for the 151 
Cobas assay at optimal Cp cut-off value at 46.7 (Figure 1). Significant difference could be observed 152 
between the AUC of the two assays (P=0.0002).  153 
About the processing time, the Abbott RealTime MTB assay required 6 hours for the detection 154 
of 46 specimens plus 2 controls in each batch. The sample inactivation, nucleic acid extraction and PCR 155 
amplification mixture preparation steps took 4 hours while the amplification needed 2 hours. The 156 
automated extraction and detection design of the Abbott RealTime MTB assay could minimize the actual 157 
manual handling time to 0.5 hour. For handling the same number of specimens by using the Cobas 158 
TaqMan MTB assay, 1.5 hour was required for nucleic acid extraction and another 0.5 hour was required 159 
for PCR amplification mixture preparation. The PCR amplification step required another 4 hours for 160 
completion, which made the total processing time to 6 hours. Since the extraction and PCR amplification 161 
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mix preparation for the Cobas assay required manual processing, the actual labor handling time for this 162 
assay could be up to 2 hours for handling every 46 specimens. 163 
 164 
Prospective analysis of diagnostic performance for Abbott RealTime MTB assay 165 
In order to further evaluate the clinical performance of the Abbott assay, a total of 532 sputum 166 
samples were collected within the study period. All specimens were tested by culture, smear staining and 167 
the Abbott assay (Table 3). After excluding 12 culture contaminated specimens, results of 520 specimens 168 
were included for diagnostic performance analysis. Among the 520 specimens, 42 of them were 169 
confirmed to be NTM including M. avium complex, M. abscessus/chelonae, M. celatum, M. kansasii, M. 170 
gordonae, M. neoaurum and M. xenopi by 16S rRNA gene sequencing. All these 42 NTM were 171 
determined as PCR negative in the Abbott RealTime MTB assay. 172 
 173 
Smear positive specimens 174 
A total of 63 out of 520 specimens (12.1%) were AFB smear positive. All specimens showed 175 
concordant results (48 positives and 15 negatives) between the Abbott RealTime MTB assay and MTB 176 
culture after reviewing the medical history of the discrepant cases. The Abbott assay was found to have 177 
100% sensitivity and 100% specificity among the smear positive specimens after discrepancies had been 178 
resolved. 179 
 180 
Smear negative specimens 181 
For smear negative specimens, a total of 457 out of 520 specimens (87.9%) were collected. 182 
There were 425 specimens showing concordant results (78 positives and 377 negatives) between the 183 
Abbott RealTime assay and culture after reviewing the clinical symptoms and medical history of the 184 
discrepant cases. There were still 2 PCR positive but culture negative cases remaining unresolved. The 185 
Abbott assay showed a 100% sensitivity and 99.5% specificity among the smear negative specimens 186 
after resolving the discrepancies. 187 
 188 
Overall performance of Abbott RealTime MTB assay 189 
Overall, the RealTime MTB assay yielded 520 (99.6%) concordant results (126 positives and 190 
394 negatives) with the MTB culture. The overall sensitivity, specificity, PPV and NPV of the Abbott 191 
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assay were 100%, 99.5%, 98.4%, and 100% respectively (Table 3). According to the statistical findings, 192 
the ROC curve for the RealTime MTB assay showed that the area under curve was 0.999 (95% CI: 0.991-193 
1.000).  ġ194 
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DISCUSSION 195 
 196 
Early diagnosis and initiating treatment are vital steps for tuberculosis infection control and 197 
patient care. Due to the low sensitivity of smear staining and the long incubation time of MTB bacterial 198 
culture, PCR-based tests with high sensitivity and short turn-a-round time had been widely used in 199 
clinical mycobacteriology laboratories. In the present study, we evaluated the diagnostic performance 200 
for the new Abbott RealTime MTB automated high-throughput real-time PCR assay (maximum 94 201 
clinical specimens per batch) on clinical respiratory specimens. The performance of this new assay was 202 
also compared with the Roche Cobas TaqMan MTB assay. 203 
The new Abbott assay was demonstrated to be nearly 10-fold more sensitive than the Cobas 204 
assay. This could be due to duo-targets (multiple copies IS6110 gene and the MTBC specific PAB gene) 205 
used in Abbott assay, whereas the Cobas TaqMan assay targets solely the single copy 16S rRNA gene 206 
in MTBC. The high sensitivity of the Abbott assay could benefit the detection of low MTBC DNA load 207 
in clinical respiratory specimens. The McNemar’s test results of the two assays demonstrated the 208 
significant difference in diagnostic sensitivity of the two assays. The significantly higher AUC in Abbott 209 
assay showed that the new Abbott assay has better diagnostic performance in comparing to the widely 210 
used Roche Cobas TaqMan MTB assay.  211 
Through this evaluation, around 10% of PCR inhibition could be found by using the Cobas 212 
assay, whereas the Abbott assay did not show any inhibition among the respiratory specimens. The low 213 
PCR inhibition rate of the Abbott system could be explained by the use of multiple silica beads washing 214 
steps during the DNA extraction. These washes could significantly minimize the amount of PCR 215 
inhibitors present in the nucleic acid elutates. On the other hand, the Cobas assay used crude DNA 216 
alkaline lysis method to extract nucleic acid. The cell debris and other crude proteins in the DNA extract 217 
could become inhibitors during PCR amplification. Among these 23 Cobas PCR inhibited specimens 218 
found in this evaluation, 6 of them were actually MTB culture positive and MTB DNA could be detected 219 
in all 6 specimens by the Abbott assay. The Abbott assay seems to have advantage in handling clinical 220 
specimens with PCR inhibitors.  221 
Other than the clinical performance, the ease of handling was also compared. Although both the 222 
Abbott and Cobas assays required 6 hours for processing, we found that the actual manual handling time 223 
for the Abbott system (0.5 hours) is much less than that of the Cobas TaqMan MTB system (2 hours). 224 
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 10 
The difference is mainly due to the fully automated extraction steps in the Abbott assay versus the manual 225 
alkaline lysis extraction steps in the Cobas assay. The shortening of labor manual handling time can 226 
benefit the human resources management in clinical laboratories. 227 
 From the prospective analysis in this study, the Abbott assay demonstrated high sensitivity 228 
(100%) and specificity (99.5%) on respiratory specimens. These performance values of the Abbott 229 
system were better than those reported in various studies for the Cobas TaqMan MTB assay [8, 14-17]. 230 
The high sensitivity and specificity indicated that the chance of production of false positives and 231 
negatives in the Abbott system was low. The high overall PPV (98.4%) and NPV (98.4%) of the Abbott 232 
assay indicated that the new system has high precision and specificity to MTBC and it is reliable for 233 
excluding NTM in clinical specimens. 234 
For the smear positive specimens, the Abbott assay showed perfect sensitivity and specificity 235 
on both culture positive and negative specimens. This indicates that the Abbott system has superior 236 
performance in detection of MTBC in AFB smear positive specimens. Among the smear negative 237 
specimens, high sensitivity (100%) PPV (97.5%) was also observed for the Abbott assay.  238 
In conclusion, the diagnostic performance of the CE-IVD Abbott RealTime MTB assay was 239 
comparable to the widely using Roche Cobas TaqMan MTB assay. The new Abbott assay has both high 240 
sensitivity and specificity to either AFB smear positive and negative respiratory specimens. The 241 
automated extraction steps of the Abbot system can significantly shorten the labor manual handling time 242 
and this can benefit the laboratory management. Therefore, our study results suggest that this new Abbott 243 
RealTime MTB assay can be a good candidate for routine M. tuberculosis complex detection in clinical 244 
laboratories.  245 
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FIGURE AND TABLE LEGENDS 291 
 292 
TABLE 1 293 
Limit of detection of the Abbott RealTime MTB and Roche Cobas TaqMan MTB assays  294 
 295 
TABLE 2 296 
Diagnostic performance comparison of the Abbott RealTime MTB and Roche Cobas TaqMan MTB 297 
assays, with M. tuberculosis culture results as the gold standard 298 
 299 
TABLE 3 300 
Diagnostic performance of the Abbott RealTime MTB assay on 520 clinical specimens 301 
 302 
FIGURE 1 303 
ROC curve of the Cobas TaqMan MTB and Abbott RealTime MTB assays. The area under curve (AUC) 304 
was 1.000 with Ct cut-off at 40.7 for the Abbott assay and 0.880 with Cp cut-off at 46.7 for the Cobas 305 
assay. 306 
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